Gilead Mobilizes Rapid Donation of Remdesivir to Support Ebola Response, Building on Decade-Long Commitment to Outbreak Relief

FOSTER CITY, Calif.--(BUSINESS WIRE)-- #Ebola--Gilead Sciences today announced a donation of more than 2,000 vials of its intravenous antiviral therapy, remdesivir, to the Republic of Uganda to support response efforts to the current outbreak of Ebola Bundibugyo virus disease (BVD). This donation, along with the additional supply being readied, continues the company's long-standing work to address emerging infectious diseases.“At Gilead, we recognize the urgency and human toll of global health emergencie.

Business Wire • Jun 12, 2026

National AIDS Memorial and the Gilead Foundation Launch Major Investment to Expand HIV/AIDS Education and Community Leadership

SAN FRANCISCO & FOSTER CITY, Calif.--(BUSINESS WIRE)--The National AIDS Memorial together with the Gilead Foundation today announced a transformative three-year, ~$3 million commitment to help preserve the history of the HIV epidemic, expand public education and engagement, and inspire the next generation of leaders advancing access to care. The fight against HIV/AIDS has always depended on more than medicine. It has required scientific innovation, public education, activism, compassion, commun.

Business Wire • Jun 11, 2026

Healthcare ETFs: From Broad Exposure to Big Breakthroughs

With AI and space dominating many of the market's most popular investment themes, it can be difficult to find differentiated opportunities. Healthcare is often viewed as one of the more defensive sectors, supported by relatively steady demand regardless of the economic environment.

ETF Trends • Jun 11, 2026

Pharma and Biotech M&A Boom Accelerates as Companies Expand Pipelines

Pharma and biotech dealmaking is surging in 2026 as companies pursue acquisitions to expand pipelines, strengthen portfolios and drive growth.

Zacks Investment Research • Jun 11, 2026

Can Gilead Sciences HIV Franchise Drive Long-Term Growth?

Gilead's HIV franchise gains momentum as Biktarvy and Descovy drive growth, Yeztugo outlook rises, and late-stage pipeline advances.

Zacks Investment Research • Jun 10, 2026

Gilead Sciences, Inc. (GILD) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Gilead Sciences, Inc. (GILD) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Seeking Alpha • Jun 10, 2026

Gilead And Merck End Trodelvy-Keytruda Lung Cancer Trial

On Monday, Gilead Sciences Inc. (NASDAQ:GILD) and Merck & Co. Inc. (NYSE:MRK) on Monday discontinued the Phase 3 KEYNOTE-D46/EVOKE-03 trial evaluating Trodelvy plus Keytruda in previously untreated metastatic non-small cell lung cancer with high PD-L1 expression, following a Data Monitoring Committee review of progression-free survival and interim overall survival data.

Benzinga • Jun 9, 2026

Gilead, Merck Report Positive Phase III HIV Study Data, End NSCLC Study

Gilead and Merck report positive phase III results for once-weekly HIV regimen islatravir/lenacapavir, while ending a lung cancer study.

Zacks Investment Research • Jun 9, 2026

Assembly Biosciences Teases Gilead HSV-2 Decision, Liver Disease Data Ahead

Assembly Biosciences NASDAQ: ASMB outlined its antiviral and liver disease development strategy during a fireside chat at the 47th Annual Goldman Sachs Healthcare Conference, highlighting upcoming decisions tied to its herpes simplex virus type 2 program, expansion of its hepatitis delta candidate into cholestatic liver diseases and expected clinical data readouts in 2027 and 2028.

MarketBeat • Jun 8, 2026

Merck and Gilead Provide Update on Phase 3 KEYNOTE-D46/EVOKE-03 Study

RAHWAY, N.J. & FOSTER CITY, Calif.--(BUSINESS WIRE)---- $MRK #MRK--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Gilead Sciences, Inc. (Nasdaq: GILD) today announced the discontinuation of the Phase 3 KEYNOTE-D46/EVOKE-03 study investigating Gilead's Trodelvy® (sacituzumab govitecan-hziy) in combination with KEYTRUDA® (pembrolizumab), Merck's anti-PD-1 therapy, compared to KEYTRUDA monotherapy in certain patients with previously untreated metastatic non-small cell lung cancer,.

Business Wire • Jun 8, 2026